一种新的靶向B7-H3的fc增强人源化单克隆抗体抑制ESCC的生长

IF 7.2 2区医学

Oncoimmunology Pub Date : 2023-11-27 DOI:10.1080/2162402x.2023.2282250

Huiting Wu, Chang Liu, Qiang Yuan, Yan Qiao, Yongwei Ding, Lina Duan, Wenjing Li, Mengjia Zhang, Xuhua Zhang, Yanan Jiang, Jing Lu, Ziming Dong, Tao Wang, Kangdong Liu, Jimin Zhao

{"title":"一种新的靶向B7-H3的fc增强人源化单克隆抗体抑制ESCC的生长","authors":"Huiting Wu, Chang Liu, Qiang Yuan, Yan Qiao, Yongwei Ding, Lina Duan, Wenjing Li, Mengjia Zhang, Xuhua Zhang, Yanan Jiang, Jing Lu, Ziming Dong, Tao Wang, Kangdong Liu, Jimin Zhao","doi":"10.1080/2162402x.2023.2282250","DOIUrl":null,"url":null,"abstract":"Esophageal squamous cell carcinoma (ESCC) is a prevalent malignant tumor of the digestive tract with a low 5-year survival rate due to the lack of effective treatment methods. Although therapeutic ...","PeriodicalId":19683,"journal":{"name":"Oncoimmunology","volume":null,"pages":null},"PeriodicalIF":7.2000,"publicationDate":"2023-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC\",\"authors\":\"Huiting Wu, Chang Liu, Qiang Yuan, Yan Qiao, Yongwei Ding, Lina Duan, Wenjing Li, Mengjia Zhang, Xuhua Zhang, Yanan Jiang, Jing Lu, Ziming Dong, Tao Wang, Kangdong Liu, Jimin Zhao\",\"doi\":\"10.1080/2162402x.2023.2282250\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Esophageal squamous cell carcinoma (ESCC) is a prevalent malignant tumor of the digestive tract with a low 5-year survival rate due to the lack of effective treatment methods. Although therapeutic ...\",\"PeriodicalId\":19683,\"journal\":{\"name\":\"Oncoimmunology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":7.2000,\"publicationDate\":\"2023-11-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncoimmunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/2162402x.2023.2282250\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncoimmunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/2162402x.2023.2282250","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

食管鳞状细胞癌(ESCC)是一种常见的消化道恶性肿瘤，由于缺乏有效的治疗方法，其5年生存率低。虽然治疗……

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC

Esophageal squamous cell carcinoma (ESCC) is a prevalent malignant tumor of the digestive tract with a low 5-year survival rate due to the lack of effective treatment methods. Although therapeutic ...

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Oncoimmunology ONCOLOGY-IMMUNOLOGY

CiteScore

12.80

自引率

2.80%

发文量

276

期刊介绍： Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.